JUN and prostate carcinoma: Similar downregulation of MMP-2 and MMP-9 levels has been observed in prostatic carcinoma by inhibiting the signaling of JNK, PI3K, Akt to reduce NF-κB and AP-1 DNA-binding activities [107].